Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.45 |
| ▸ | NPY4R | P50391 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | NPY1R | P25929 | 3/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NMT2 | O60551 | 2/20 | 0.39 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13184779 | 0.93 | GLP1R (0.50) | GLP1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL13184781 | 0.83 | GLP1R (0.53) | GLP1RNMT2NMT1 | |
| SCHEMBL13184776 | 0.82 | GLP1R (0.54) | GLP1RNMT2NMT1 | |
| SCHEMBL3503977 | 0.78 | NPY4R (0.52) | GLP1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL14351275 | 0.78 | NPY4R (0.52) | GLP1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL2150776 | 0.77 | NPY4R (0.51) | GLP1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL13907995 | 0.76 | NPY4R (0.55) | NPY4RNPY5RNPY1RNPY2RNMT2 | |
| SCHEMBL13707032 | 0.74 | SIRT5 (0.47) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL13624777 | 0.74 | SIRT5 (0.47) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL12073161 | 0.73 | SIRT5 (0.55) | NPY4RNPY5RNPY1RNPY2RNMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | NOVO NORDISK A/S (DK) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | IAPP, GLP1R, ALB | GLP1R 2/4885NPY4R 190/4885NPY5R 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.